Welcome to our dedicated page for QIAGEN N.V. news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on QIAGEN N.V. stock.
QIAGEN N.V. (symbol: QGEN) is a leading global provider of sample-to-insight solutions that transform biological materials into valuable molecular insights. The company's sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Its assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases from QIAGEN interpret data to report relevant, actionable insights. Automation solutions tie these components together in seamless and cost-effective molecular testing workflows.
QIAGEN serves a diverse customer base of over 500,000 worldwide in sectors such as molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharmaceutical and biotechnology companies), and academia (life sciences research). As of June 30, 2015, the company employed approximately 4,400 people across 35 locations globally. Additional information can be found on their website at http://www.qiagen.com.
QIAGEN's proprietary sample and assay technology enables the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The company's revenue is almost evenly split between life sciences and molecular diagnostics applications, with nearly 90% of its revenue derived from consumables and the remaining from instrumentation and related services. The largest portion of QIAGEN's revenue comes from the Americas (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Recent achievements include:
- Q1 2024 net sales of $459 million (-5% at actual rates, -5% at constant exchange rates, CER), with a diluted EPS of $0.36 and an adjusted diluted EPS of $0.46. The net sales at CER of $462 million were ahead of the outlook for at least $455 million CER, and the adjusted diluted EPS of $0.47 CER was ahead of the $0.44 CER outlook.
- Strong operating cash flow rose by 85% to $133 million versus Q1 2023.
- The QCI Secondary Analysis software, integrated with QCI Interpret, facilitates high-throughput secondary analysis of clinical next-generation sequencing data.
- Collaborations aimed at creating novel digital PCR assays to improve DNA analysis in forensics and human identification.
- Introduction of the QIAstat-Dx Respiratory Panel Plus for accurate diagnosis of respiratory infections, capable of generating results in about one hour with minimal hands-on time.
- Enhancements to the QIAGEN Clinical Insight Interpret platform, which has processed over 4 million NGS patient test cases for oncology and hereditary diseases worldwide.
- New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis, complementing the company's existing assay offerings.
QIAGEN continues to innovate and maintain its leading position in the molecular diagnostics and life sciences industries. The company's ongoing efforts to expand its product offerings and enhance its technologies ensure that it remains a trusted partner for researchers and healthcare providers worldwide.
QIAGEN announced its 2028 strategy at the Capital Markets Day in New York. The company targets about 7% compound annual sales growth (CAGR) at constant exchange rates (CER) from 2024-2028 and aims for a 31% CER adjusted operating income margin by 2028. This strategy includes significant investments in R&D and digital initiatives, streamlining the portfolio, and launching new products. QIAGEN also plans to return at least $1 billion to shareholders and pursue value-creating M&A opportunities. Key growth pillars include digital PCR, syndromic diagnosis, digital insights, sample technologies, and the QuantiFERON-TB Gold Plus test.
QIAGEN announced a new version of its clinical decision support software, QCI Interpret, tailored for high-throughput NGS labs. The update boosts performance, scalability, and user collaboration, significantly improving turnaround times, diagnostic yield, and result quality. Key features include bulk variant assessment, co-occurring variant flagging, and enhanced multi-user functionality. These enhancements address the growing demands of genomics labs, enabling seamless test expansion without compromising efficiency. The software, which processes over 850,000 clinical samples annually, now offers faster, more reliable variant analysis, and has received European IVDR certification as a Class C Medical Device.
QIAGEN has released its 2023 Sustainability Report, showcasing significant progress on its Environmental, Social, and Governance (ESG) commitments.
Key environmental achievements include a 15% reduction in Scope 1 and 2 emissions, primarily through increased green energy procurement, and a 7% reduction in plastic usage.
Socially, QIAGEN has expanded diagnostic access globally, committed to at least 40% female leadership by 2027, and achieved top scores for LGBTQ+ inclusion.
Governance improvements feature an updated Supplier Code of Conduct and the formation of a Human Rights Committee. ESG goals are incorporated into employee compensation, now representing 20% of annual variable pay.
QIAGEN's sustainability efforts have been recognized with high ratings from MSCI ESG Research, ISS-ESG, and Sustainalytics.
QIAGEN unveils 35 new digital PCR Microbial DNA Detection Assays for its QIAcuity platform, targeting pathogens behind tropical diseases, sexually transmitted infections (STIs), and urinary tract infections (UTIs). This expansion is part of a broader strategy to enhance microbial research, increasing QIAGEN's total microbial dPCR assay portfolio to over 680 targets. The assays offer high precision and sensitivity, supporting infectious disease research and public health efforts. QIAGEN will present these advancements at the ASM Microbe conference from June 13-17, 2024, in Atlanta.
QIAGEN (NYSE: QGEN) announced its decision to discontinue the NeuMoDx 96 and 288 Molecular Systems due to changing market dynamics post-COVID-19. This move aims to redirect resources towards more promising segments like the QIAstat-Dx system, QIAcuity digital PCR systems, and QIAGEN Digital Insights (QDI) bioinformatics. The company will support NeuMoDx customers during a transition period extending into 2025.
QIAGEN reaffirmed its Q2 2024 outlook with net sales of at least $495 million CER and adjusted diluted EPS of $0.52 CER. The full-year 2024 adjusted diluted EPS outlook is updated to $2.14 CER. A pre-tax restructuring charge of approximately $400 million, including $300 million in non-cash charges, will be recognized primarily in Q2 2024.
Discussions with NeuMoDx customers are ongoing to assess the impact on the projected 2024 sales of $55 million CER, with further details to be provided in Q2 2024 results.
QIAGEN has introduced a new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis on its QIAcuity platform.
This tool complements QIAGEN's existing pre-designed assays and enhances the GeneGlobe Design and Analysis Hub.
GeneGlobe now features improved user experience, including collaborative panel design and faster pathway map rendering via Ingenuity Pathway Analysis.
These upgrades aim to support diverse assay customization needs, accelerating drug discovery and other research applications.
QIAGEN plans to expand the dPCR tool capabilities to include microbial and somatic mutation assays later in 2024.
QIAGEN has launched the QIAstat-Dx Gastrointestinal Panel 2 in the U.S. following FDA clearance for clinical use. The panel identifies up to 16 GI pathogens in about an hour using real-time PCR technology, improving the efficiency and accuracy of GI infection diagnoses. Acute infectious gastroenteritis is a major health concern in the U.S., with 180 million cases annually. The panel's rapid detection reduces the need for lengthy traditional tests and helps healthcare providers quickly isolate contagious patients. Additionally, it supports antimicrobial stewardship by reducing unnecessary antibiotic use. The QIAstat-Dx system is widely used with over 4,000 installations globally, and it features cloud-based connectivity for remote monitoring and epidemiological insights.
QIAGEN and Myriad Genetics have announced a collaboration to develop a kit-based test for Homologous Recombination Deficiency (HRD). This next-generation sequencing (NGS) test leverages QIAGEN’s QIAseq xHYB technology and Myriad’s FDA-approved MyChoice CDx biomarkers.
The test will support research and companion diagnostics development, aiding personalized medicine for ovarian and other solid tumors. The goal is to enhance decentralized testing, reduce therapy decision times, and lower associated costs.
The MyChoice CDx assay can identify 34% more HRD tumors compared to other methods. This initiative builds on a recently announced collaboration agreement and aims to expand the accessibility and clinical adoption of HRD testing globally.
QIAGEN has introduced its QIAseq Multimodal DNA/RNA Lib Kit, designed to streamline the preparation of DNA and RNA libraries from a single sample for next-generation sequencing (NGS). This new kit aids multiomics studies, important for precision medicine and understanding complex diseases like cancer.
It offers a simplified workflow for whole genome and transcriptome sequencing, reducing sample material and time required. The kit supports various sample types, including blood, FFPE samples, and cfDNA, and is compatible with multiple sequencing platforms, such as Illumina and Element Aviti.
The QIAseq Multimodal Kit's flexibility in generating DNA-only or RNA-only libraries, as well as combined DNA/RNA libraries, enhances efficiency and saves resources in NGS labs. The kit adds to QIAGEN's NGS technology portfolio, which is pivotal in biomarker research and disease surveillance.
QIAGEN has received European IVDR certification for its QIAGEN Clinical Insight Interpret, a clinical decision support software for next-generation sequencing (NGS) in oncology and hereditary applications. This certification ensures the platform complies with the EU's regulatory framework, enhancing patient safety, data transparency, and traceability. The software has already processed over 4 million NGS patient test cases globally. The certified version will be available in Europe by late 2024, facilitating faster and more accurate clinical decision-making.
FAQ
What is the current stock price of QIAGEN N.V. (QGEN)?
What is the market cap of QIAGEN N.V. (QGEN)?
What does QIAGEN N.V. do?
How many employees does QIAGEN N.V. have?
What are QIAGEN's recent financial achievements?
What industries does QIAGEN serve?
What are QIAGEN’s proprietary technologies?
Where can I find more information about QIAGEN?
What are some of QIAGEN's recent innovations?
How is QIAGEN's revenue split?
Which regions contribute most to QIAGEN's revenue?
What is the QIAstat-Dx Respiratory Panel Plus?
